Lung Cancer

Top Story

Plasma analysis shows promise for NSCLC T790M genotyping

Plasma analysis shows promise for NSCLC <i>T790M</i> genotyping
August 23, 2016

Patients with T790M–positive advanced non–small cell lung cancer demonstrated similar outcomes with osimertinib whether the T790M mutation was detected using plasma analysis or a tissue-based assay, according to a retrospective analysis of the AURA trial.

Thus, plasma analysis may provide a less invasive diagnostic alternative to undergoing a tumor biopsy to detect acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors, according to the researchers.

Five clinical trial updates you may have missed

August 19, 2016
Several pharmaceutical companies have provided updates this month on phase 2 or phase 3 trials. HemOnc Today provides this overview of five clinical trial…

ASTRO Annual Meeting to reflect theme of ‘enhancing value, improving outcomes’

August 18, 2016
The American Society for Radiation Oncology will hold its annual meeting from Sept. 25 to 28 in Boston. More than 10,000 people are expected to attend, making this one…
In the Journals Plus

Incidence of PD-1 inhibitor–related pneumonitis highest in NSCLC, renal cell carcinoma

August 18, 2016
PD-1 inhibitor–related pneumonitis occurred most frequently among patients with non–small cell lung cancer or renal cell carcinoma, according to results of a…
CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
Video
Meeting News Coverage

VIDEO: Adverse events less common with immuno-therapy, still require patient, provider education and early recognition and treatment

August 1, 2016
More »
Featured
Discoveries from ASCO 2016: Breast Cancer

Discoveries from ASCO 2016: Breast Cancer

CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
In the Journals Plus

Plasma analysis shows promise for NSCLC T790M genotyping

August 23, 2016
Patients with T790M–positive advanced non–small cell lung cancer demonstrated similar outcomes with osimertinib whether the T790M

Five clinical trial updates you may have missed

August 19, 2016
Several pharmaceutical companies have provided updates this month on phase 2 or phase 3 trials. HemOnc Today provides this overview of five…

ASTRO Annual Meeting to reflect theme of ‘enhancing value, improving outcomes’

August 18, 2016
The American Society for Radiation Oncology will hold its annual meeting from Sept. 25 to 28 in Boston. More than 10,000 people are expected to…

In the Journals Plus

Incidence of PD-1 inhibitor–related pneumonitis highest in NSCLC, renal cell carcinoma

August 18, 2016
PD-1 inhibitor–related pneumonitis occurred most frequently among patients with non–small cell lung cancer or renal cell carcinoma…

In the Journals Plus

Cancer survivors report similar sexual activity, function as others their age

August 17, 2016
Sexual activity and function appeared no different in cancer survivors than in cancer-free adults aged 50 years or older, according to results of a…

Initiative fuels advancement, access of immuno-oncology in community setting

August 17, 2016
The approval and availability of new immunotherapy treatments sparked the need for dissemination of these therapies to patients throughout the cancer…

In the Journals Plus now live on Healio.com/HemOnc

August 17, 2016
Healio.com/HemOnc has launched In the Journals Plus, a new feature that will provide busy physicians with summaries of the top articles from leading…

Custirsen fails to extend OS in metastatic castrate-resistant prostate cancer

August 16, 2016
A phase 3 trial designed to evaluate custirsen in men with metastatic castrate-resistant prostate cancer whose disease progressed after docetaxel…

Oncofertility experts help physicians, patients understand reproductive consequences of cancer treatment

August 15, 2016
Life-preserving treatments once frequently threatened the fertility of patients with cancer. However, fewer barriers exist today thanks to increasing…

In the Journals Plus

Ceritinib effectively treats ALKrearranged NSCLC

August 14, 2016
Ceritinib may safely and effectively treat patients with ALKrearranged non–small cell lung cancer, including those with disease…

More Headlines »
morganatic-roan